The global crohn’s disease (CD) treatment market is poised for substantial growth, projected to reach a value of approximately USD 17.80 billion by the end of 2033, up from USD 11.68 billion at the end of 2023. This revelation comes from a comprehensive report by Future Market Insights, showcasing a steady compound annual growth rate (CAGR) of 4.3% over the next decade.
The increasing incidence of Crohn’s disease and ulcerative colitis worldwide is the primary catalyst for this upward trajectory. As awareness and understanding of these conditions continue to spread, the demand for effective treatment options intensifies, fostering robust market expansion.
Request for a Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-16809
One of the key driving forces behind this growth is the advancement in treatment modalities, notably the use of biologics such as adalimumab, infliximab, certolizumab, and golimumab. These innovative therapies offer enhanced efficacy and represent a significant leap forward in managing Crohn’s disease and ulcerative colitis.
The report underscores the pivotal role played by biologics in shaping the landscape of Crohn’s disease treatment, providing healthcare professionals and patients with more targeted and personalized approaches to care.
“As the global burden of Crohn’s disease and ulcerative colitis continues to rise, there is an urgent need for effective treatment options,” said FMI. “The projected growth of the Crohn’s disease treatment market reflects not only the increasing prevalence of these conditions but also the strides made in therapeutic innovation. This presents an opportunity for stakeholders to collaborate and drive further advancements in patient care.”
With the global Crohn’s disease treatment market poised for significant expansion, stakeholders across the healthcare spectrum are encouraged to prioritize research, innovation, and collaboration to meet the evolving needs of patients worldwide.
Key Takeaways from the Market Study:
- The Crohn’s disease treatment market expanded historically between 2018 and 2022 at a CAGR of 3.2%.
- More than $11.2 billion is presently spent on treating Crohn’s disease globally.
- Immunomodulators are predicted to lead the medication type sector in 2023 with a 53% revenue share.
- The hospital pharmacy sector by distribution channel will maintain the second-largest segment during the anticipated period, with a global market share of 27.3% in 2023.
- From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 4.9%.
- From 2023 to 2033, the Asia Pacific Crohn’s Disease Treatment Market is anticipated to expand at a stable CAGR of 3.6%.
“The increasing prevalence of ulcerative colitis and Crohn’s disease along with innovative pipeline of biological therapies and medications are expected to accelerate the growth during the forecast period,” comments a Future Market Insights analyst.
Customization with Our Report: https://www.futuremarketinsights.com/customization-available/rep-gb-16809
Competitive Landscape:
Some of the top players in the global intraocular lymphoma disease market are:
- Abbvie Inc.
- Celgene Corporation
- Genetech
- Johnson & Johnson
- Pfizer
- Prometheus Laboratories Inc. (Nestle)
- Salix Pharmaceuticals Inc.
- Takeda’s Pharmaceutical Ltd
- Janssen Pharmaceuticals
- Biogen
- AstraZeneca
Some of the recent developments in this domain are:
- In 2022, AbbVie said that SKYRIZI® (risankizumab-rzaa) has received FDA approval to be used in the management of moderately to highly active Crohn’s disease. The interleukin-23 (IL-23) inhibitor SKYRIZI binds to the p19 component of IL-23 to specifically inhibit it. A variety of chronic immune-mediated disorders, including Crohn’s disease, are suspected to be related to IL-23, a cytokine implicated in inflammatory processes.
- Tiziana Life Sciences, a biotechnology firm that enables breakthrough immunotherapies through innovative modes of monoclonal antibody administration, announced the start of a Phase 1b clinical study in 2022 to test foralumab enteric-coated capsules orally delivered in people who have mild to moderate Crohn’s Disease (CD). A unique method of inducing an anti-inflammatory immune reaction by site-targeted immunomodulation in the intestine is oral administration of foralumab.
Key Segments Covered in the Crohn’s Disease Treatment Market Report:
By Drug Type:
- Antibiotics
- Amino Salicylates
- Corticosteroids
- Immunomodulators
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
A Full Report Analysis: https://www.futuremarketinsights.com/checkout/16809
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube